Today in the European Union, we can be proud and celebrate the fact that in 28 EU Member States, biosimilar medicines are in use, and competition in the biological medicines field has consistently brought value for patients and healthcare communities. In general, broader access (more patients treated) is an immediate consequence of biosimilar competition, and earlier access to treatment (where clinically appropriate) has been observed in a number of countries.
Julie Maréchal-Jamil, MScDirector, Biosimilars Policy and ScienceMedicines for Europe
Today in the European Union, we can be proud and celebrate the fact that in 28 EU Member States, biosimilar medicines are in use, and competition in the biological medicines field has consistently brought value for patients and healthcare communities. In general, broader access (more patients treated) is an immediate consequence of biosimilar competition, and earlier access to treatment (where clinically appropriate) has been observed in a number of countries.
A concern is that future access to biological therapies, including their biosimilars, has not been getting the attention it really deserves. The biological medicines portfolio set to lose exclusivity over the next decade bears little resemblance to the ones we’ve experienced thus far. Thoughtful adjustments to existing frameworks will therefore be needed to secure continuous benefits from biosimilar competition over time. Now, how do we do that?
The primary colors of a sustainable biosimilar opportunity
As with primary colors, experience has taught us that there are certain rules which, when mixed and adapted, foster different colors of a sustainable biosimilar opportunity.
When comparing and contrasting stories from EU Member States, one has to acknowledge that the disparities in stakeholder awareness, understanding, and empowerment on biosimilar medicines topics are tremendous. It is therefore by design that some countries, such as Denmark, Germany, or the United Kingdom have managed to bring all the important stakeholders onboard the biosimilar train. At the International Society for Pharmacoeconomics and Outcomes Research 2019 meeting, held November 2-6 in Copenhagen, Denmark,1 it was striking to see that, despite 13 years of biosimilar medicines experience in the European Union, a large proportion of EU medicines agencies still lack the minimum information on these medicines, constituting the very first barrier to biosimilar adoption.
Hearing directly from some EU Member States at the recent annual European Commission multistakeholder workshop, held on October 29, 2019, it was clearly apparent that benefits can only be obtained if biosimilar medicines are used in clinical practice. Whereas in Germany, physician associations report great biosimilar uptake and evolving prescription trends, in Slovakia, the existing framework appears to disincentivise by design the use of biosimilar medicines. Stakeholders concurred in discussions that a sole focus on price erosion fails to create a conducive environment for competition in the market, as does the shift from one monopoly (originator) to another monopoly (biosimilar).
While benefit-sharing has been emulated across the European Union and internationally (eg, in Canada), it remains a rather underused policy intervention. Transparent reallocation of the biological medicines budget has been introduced in the United Kingdom and more recently in France, by means of a pilot project whereby the prescription of a selection of biosimilar medicines rewards the hospital departments involved in the prescription for reinvestment in patient care.
Obviously, when seeking the optimal shade of color, failing to combine these 3 primary colors will not deliver on the promise of earlier, broader, and future access to biological medicines and healthcare. To date, a limited number of EU Member States successfully combine trust, competition, and sense of purpose, translating into variable benefits in terms of access. In certain instances, continuous learning from experience has allowed policy frameworks to morph and get significantly ahead of the game.
The good news is that there is a lot of cumulated experience at national, regional, and local levels. Many color combinations have been tried out, and progress has been made in extending the reference color palette.
The ideas are there, the implementation is on the way, and the results should be as well where time is allowed for measures to bear fruit and where monitoring informs policy-making via feedback mechanisms.
Beyond primary colors: the political outlook, sustainability of healthcare systems, and equitable access to all medicines
The EU institutions are currently getting organised for the next 5 years, and this is an opportunity to shape future-proof biosimilar and access frameworks.
So we have a plan: earlier, broader, and future access will drive the evolution on the EU biosimilar policy framework to ensure that national healthcare systems deliver on their commitment to more equity in access to health and healthier communities.
We are planning to take the pulse on these various aspects at the occasion of our upcoming Biosimilar Medicines Conference on March 26-27, 2020, in Amsterdam; check our programme online on November 15, 2019.
Reference
1. Barbier L, Mbuaki A, Simoens S, Vulto AG, Huys I. The role of regulatory guidance and information dissemination for biosimilar medicines—the perspective of healthcare professionals and industry. Presented at: ISPOR Europe 2019; November 2-6, 2019; Copenhagen, Denmark.
Biosimilar Policy Roundup—September 2024
October 1st 2024In September 2024, the FDA approved a new biosimilar for treating retinal conditions, marking a significant development in the biosimilars landscape, coinciding with ongoing legal disputes in the industry and highlighting broader trends in market dynamics and regulatory challenges.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
French Study Finds High Patient Satisfaction With Adalimumab Biosimilar Treatment for IBD
September 21st 2024An observational study assessing patient satisfaction with adalimumab for inflammatory bowel disease (IBD) reported a high level of satisfaction with all adalimumab product, including biosimilars.
AAM Report: Generics and Biosimilars Savings Reach $445 Billion in 2023, Part 1
September 18th 2024Savings from generic and biosimilar drugs totaled $445 billion in 2023, showing promise for the growth of both markets and highlighting the success of expansion policies for these products, according to a new report from the Association for Accessible Medicines (AAM).